Research Reports

Key takeaways

Femasys Inc. appointed John Canning, age 52, as COO effective March 30, 2026.

Canning's prior roles: COO at Terumo Aortic (2017-2026), Bolton Medical (2003-2017), Medtronic (1999-2003).

Annual base salary of $450,000; target bonus 40% of base salary.

Inducement stock option for 150,000 shares at Nasdaq closing price on March 30, 2026; vests 25% annually over 4 years.

Severance: 9 months base salary, COBRA if terminated without cause or for good reason.

No family relationships, prior transactions, or arrangements with Canning.

Full analysis

Femasys Inc. strengthened its leadership by appointing John Canning as COO, bringing over 25 years of medical device experience from senior roles at Terumo Aortic, Bolton Medical, and Medtronic. The employment agreement provides competitive compensation including a $450,000 base salary, 40% target bonus, and a significant 150,000-share inducement option outside the 2021 Equity Incentive Plan under Nasdaq Rule 5635(c)(4). Vesting is structured for retention with 25% annually over four years. Termination protections include nine months of salary continuation and COBRA subsidies without cause or for good reason, subject to a release. This hire supports operational execution and commercial growth for Femasys' fertility and birth control products amid ongoing commercialization efforts.

FEMY · Femasys Inc.

Summary

Key takeaways

Full analysis